Phase II study of a weekly 24-hour infusion with 5-fluorouracil and simultaneous sodium-folinic acid in the first-line treatment of metastatic colorectal cancer

被引:17
|
作者
Hartung, G
Hofheinz, RD
Wein, A
Riedel, C
Rost, A
Fritze, D
Kreuser, ED
Drees, M
Kühnel, J
Hehlmann, R
Queisser, W
机构
[1] Univ Klinikum Rostock, Hamatol Onkol Abt, Klin & Poliklin Innere Med, D-18057 Rostock, Germany
[2] Univ Heidelberg, Onkol Zentrum, Med Klin 3, Univ Klinikum Mannheim, Mannheim, Germany
[3] Univ Erlangen Nurnberg, Med Klin 1, D-8520 Erlangen, Germany
[4] Klinikum Darmstadt, Med Klin 5, Darmstadt, Germany
[5] Krankenhaus Barmherzigen Bruder, Med Klin, Regensburg, Germany
[6] Medac GMBH, Wedel, Germany
来源
ONKOLOGIE | 2001年 / 24卷 / 05期
关键词
colorectal cancer; phase II study; 5-fluorouracil; calcium-folinic acid; sodium-folinic acid; weekly 24-hour infusion;
D O I
10.1159/000055126
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. A weekly continuous 24-hour infusion therapy with 5-fluorouracil (5-FU) and calcium - folinic acid (CA-FA) was shown to be an effective first-line treatment in advanced metastatic colorectal cancer. Sodium - folinic acid (S-FA) is a new formulation which, in contrast to CA-FA allows the simultaneous Lv. administration in combination with 5-FU in one pump. Patients and Methods; From 1997 to 1998, 51 patients [median age 60 (range 24-77) years; 38 male, 13 female] with metastatic colorectal cancer were recruited in 5 centers to receive weekly 24-hour infusions of 5-FU (2,600 mg/m(2)) and S-FA (500 mg/m(2)) dissolved in one pump for 6 weeks as first-line treatment. The treatment cycle was repeated after a 2-week rest period. Results: 1,178 administrations (median 24, range 3-54) were performed during the study. Out of 51 patients (median follow-up 20.2 months), 2 (3.9%) achieved complete remission (CR), 17 (33.3%) partial remission (PR), and 21 (41.2%) no change (NC). Progressive disease (PD) was observed in 11/51 (21.6%) patients, including 6 patients who did not complete the first cycle. Median time to tumor progression (TTP) was 8.5 months (95% Cl: 5.8-11.3). 32/51 (62.7%) patients survived for more than 1 year, the median survival was reached at 16.5 months (95%Cl: 10.2-22.8). Among major toxicities, NCL-CTC grade III/IV diarrhea occurred in 13/51 25.4%), grade III hand-foot syndrome in 6/51 (11.7% patients. Grade III/IV stomatitis was observed in 4/51 (7.8%), cardiac toxicity occurred in 2/51 patients (3.9%). Conclusion: Similar to conventional 24-hour 5-FU + CA-FA treatment, the combination with S-FA induced 37.2% objective responses with moderate toxicity. However, TTP seems favorable and the administration of S-FA is convenient, while saving costs and time for the patient in outpatient units.
引用
收藏
页码:457 / 462
页数:8
相关论文
共 50 条
  • [31] Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer
    F Lordick
    S Lorenzen
    J Stollfuss
    U Vehling-Kaiser
    F Kullmann
    M Hentrich
    R Zumschlinge
    H Dietzfelbinger
    J Thoedtmann
    M Hennig
    T Seroneit
    R Bredenkamp
    J Duyster
    C Peschel
    British Journal of Cancer, 2005, 93 : 190 - 194
  • [32] An alternating regimen of irinotecan/5-fluorouracil/folinic acid and oxaliplatin/5-fluorouracil/folinic acid in metastatic colorectal cancer: A phase II trial
    Ferrari, V
    Valcamonico, F
    Amoroso, V
    Simoncini, E
    Vassalli, L
    Marpicati, P
    Rangoni, G
    Grisanti, S
    Pasinetti, N
    Marini, G
    ONCOLOGY, 2005, 69 (04) : 283 - 289
  • [33] Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer
    Lordick, F
    Lorenzen, S
    Stollfuss, J
    Vehling-Kaiser, U
    Kullmann, F
    Hentrich, M
    Zumschlinge, R
    Dietzfelbinger, H
    Thoedtmann, J
    Hennig, M
    Seroneit, T
    Bredenkamp, R
    Duyster, J
    Peschel, C
    BRITISH JOURNAL OF CANCER, 2005, 93 (02) : 190 - 194
  • [34] CEA and CA 19-9 measurement as a monitoring parameter in metastatic colorectal cancer (CRC) under palliative first-line chemotherapy with weekly 24-hour infusion of high-dose 5-fluorouracil (5-FU) and folinic acid (FA)
    Hanke, B
    Riedel, C
    Lampert, S
    Happich, K
    Martus, P
    Parsch, H
    Himmler, B
    Hohenberger, W
    Hahn, EG
    Wein, A
    ANNALS OF ONCOLOGY, 2001, 12 (02) : 221 - 226
  • [35] Palliative first-line therapy with weekly high-dose 5-fluorouracil and sodium folinic acid as a 24-hour infusion (AIO regimen) combined with weekly irinotecan in patients with metastatic adenocarcinoma of the stomach or esophagogastric junction followed by secondary metastatic resection after downsizing
    Koucky, Kathrin
    Wein, Axel
    Konturek, Peter C.
    Albrecht, Heinz
    Reulbach, Udo
    Maennlein, Gudrun
    Wolff, Kerstin
    Ostermeier, Nicola
    Busse, Dagmar
    Golcher, Henriette
    Schildberg, Claus
    Janka, Rolf
    Hohenberger, Werner
    Hahnd, Eckhart G.
    Siebler, Juergen
    Neurath, Markus F.
    Boxberger, Frank
    MEDICAL SCIENCE MONITOR, 2011, 17 (05): : CR248 - CR258
  • [36] Paclitaxel in combination with weekly 24-hour infusional 5-fluorouracil plus leucovorin in the second-line treatment of metastatic breast cancer: Results of a phase II study
    Klaassen, U
    Wilke, H
    Harstrick, A
    Pari, CP
    Strumberg, D
    Newmann, K
    Eberhardt, W
    Achterrath, W
    Lenaz, L
    Seeber, S
    ANNALS OF ONCOLOGY, 1998, 9 (01) : 45 - 50
  • [37] A phase II study of regional 2-weekly 5-fluorouracil infusion with intravenous folinic acid in the treatment of colorectal liver metastases
    JD Howell
    CS McArdle
    DJ Kerr
    J Buckles
    JA Ledermann
    I Taylor
    HJ Gallagher
    J Budden
    British Journal of Cancer, 1997, 76 : 1390 - 1393
  • [38] Cardiotoxicity in 5-fluorouracil folinic acid treatment for metastatic colorectal cancer
    Käfer, G
    Achtnich, M
    Willer, A
    Weiss, A
    Queisser, W
    ONKOLOGIE, 1998, 21 (04): : 324 - 327
  • [39] Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study
    Hofheinz, RD
    Gnad-Vogt, U
    Wein, A
    Saussele, S
    Kreil, S
    Pilz, L
    Hehlmann, R
    Hochhaus, A
    ANTI-CANCER DRUGS, 2005, 16 (01) : 39 - 45
  • [40] Phase II Multicentered Study of Low-Dose Everolimus plus Cisplatin and Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin as First-Line Treatment for Patients with Advanced Gastric Cancer
    Shen, Ying-Chun
    Li, Chung-Pin
    Yen, Chia-Jui
    Hsu, Chiun
    Lin, Yu-Lin
    Lin, Zhong-Zhe
    Chen, Li-Tzong
    Su, Wu-Chou
    Chao, Yee
    Yeh, Kun-Huei
    Cheng, Ann-Lii
    ONCOLOGY, 2014, 87 (02) : 104 - 113